Stockscreener 앱 받기
14.66
1.35%
-0.20
시간 외 거래:
14.49
-0.17
-1.16%
전일 마감가:
$14.86
열려 있는:
$14.69
하루 거래량:
25,088
Relative Volume:
0.32
시가총액:
$131.47M
수익:
-
순이익/손실:
$-40.62M
주가수익비율:
-0.7554
EPS:
-19.4076
순현금흐름:
$-35.63M
1주 성능:
-0.41%
1개월 성능:
-3.49%
6개월 성능:
-9.34%
1년 성능:
-4.96%
1일 변동 폭
$14.27
$14.96
1주일 범위
$13.96
$15.28
52주 변동 폭
$6.27
$27.40
Promis Neurosciences Inc Stock (PMN) Company Profile
명칭
Promis Neurosciences Inc
전화
416-847-6898
주소
SUITE 200, 1920 YONGE STREET, TORONTO
Compare PMN vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PMN
Promis Neurosciences Inc
|
14.66 | 133.26M | 0 | -40.62M | -35.63M | -19.41 |
VRTX
Vertex Pharmaceuticals Inc
|
515.55 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.93 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
987.84 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
212.00 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.51 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Promis Neurosciences Inc 주식(PMN)의 최신 뉴스
ProMIS Neurosciences (PMN) Q2 2026 Update Highlights Strong Cash Position Amid High Valuation - GuruFocus
ProMIS Neurosciences (PMN) Holds Near $14.86 as Traders Eye Key Resistance at $15.60Call Wall - dars.gov.et
PMN Maintained by Guggenheim -- Price Target Raised to $100 - GuruFocus
Guggenheim Maintains ProMIS Neurosciences(PMN.US) With Buy Rating, Raises Target Price to $100 - Moomoo
ProMIS Neurosciences Inc. Stock 12‑Month Price Target Raised to $43.64, Implies 195% Upside - TradingView
Promis Neurosciences (NASDAQ:PMN) Stock Price Expected to Rise, Guggenheim Analyst Says - MarketBeat
Chardan Capital Maintains ProMIS Neurosciences(PMN.US) With Buy Rating, Raises Target Price to $33 - Moomoo
ProMIS Neurosciences Inc (PMN) (Q2 2026) Earnings Call Highlight - GuruFocus
Promis Neurosciences Q2 Earnings Call Highlights - MarketBeat
PROMIS NEUROSCIENCES ($PMN) Releases Q2 2026 Earnings - Quiver Quantitative
Earnings call transcript: ProMIS Neurosciences posts strong cash position in Q2 2026 - Investing.com Canada
PMN: Interim phase I-B data for PMN310 showed no ARIA-E and strong biomarker signals, with cash runway through 2027 - TradingView
ProMIS Neurosciences Q2 Results: Cash Runway Extends To 2027 - scanx.trade
Promis Neurosciences (NASDAQ:PMN) Issues Quarterly Earnings Results, Beats Estimates By $0.10 EPS - MarketBeat
ProMIS Neurosciences Reports Q2 2026 Results: Full Earnings Call Transcript - Benzinga
ProMIS Neurosciences Inc. Q2 2026: Net loss $(11.73)M, Diluted EPS $(1.28) — 10-Q Summary - TradingView
ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights - The Manila Times
ProMIS Neurosciences (PMN) extends cash runway with $70.1M PIPE amid higher R&D - Stock Titan
ProMIS Neurosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
ProMIS Neurosciences Inc expected to post a loss of $1.38 a shareEarnings Preview - TradingView
ProMIS Neurosciences Inc (PMN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Insider at ProMIS Neurosciences (PMN) buys 2,280 common shares - Stock Titan
ProMIS Neurosciences Inc (PMN) Stock News Today - TradingKey
Promis Neurosciences (NASDAQ:PMN) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Promis Neurosciences (PMN) Projected to Post Earnings on Thursday - MarketBeat
Janus Henderson Group PLC Acquires New Position in Promis Neurosciences $PMN - MarketBeat
ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026 - The Manila Times
ProMIS schedules 4:30 p.m. webcast for Aug. 13 update - Stock Titan
ADAR1 Capital Management LLC Buys Shares of 95,350 Promis Neurosciences $PMN - MarketBeat
Promis Neurosciences (NASDAQ:PMN) Upgraded at Chardan Capital - MarketBeat
PMN Maintains Buy Rating by Chardan Capital -- Price Target Rais - GuruFocus
Chardan raises ProMIS Neurosciences stock price target on trial data By Investing.com - Investing.com Canada
Chardan Adjusts Price Target on ProMIS Neurosciences to $33 From $20, Maintains Buy Rating - marketscreener.com
ProMIS Neurosciences (PMN) Reports Promising Interim Biomarker D - GuruFocus
Why is ProMIS Neurosciences stock surging today? By Investing.com - Investing.com Canada
ProMIS Neurosciences (PMN) Surges 21.3% Pre-Market Ahead of Earn - GuruFocus
ProMIS Neurosciences Says PMN310 Alzheimer Drug Shows Positive Interim Safety, Biomarker Data - marketscreener.com
ProMIS Neurosciences (PMN) Reports Promising Interim Biomarker Data Amid High Valuation Expectations - GuruFocus
ProMIS Neurosciences Inc. Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in PRECISE-AD Phase 1b Alzheimer?s Disease Trial - marketscreener.com
ProMIS Neurosciences stock jumps on trial safety data By Investing.com - Investing.com South Africa
ProMIS Neurosciences stock jumps on trial safety data - Investing.com
ProMIS Reports Positive Interim PMN310 Alzheimer’s Trial Data - TipRanks
ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial - The Manila Times
ProMIS Neurosciences Reports Positive 6-Month Interim Safety and Biomarker Results for PMN310 in Phase 1b Alzheimer's Trial - Moomoo
ProMIS Neurosciences Reports Positive 6-Month Interim Safety and Biomarker Results for PMN310 in Phase 1b Alzheimer’s Trial - Quiver Quantitative
ProMIS Neurosciences (Nasdaq: PMN) reports positive six-month PMN310 Alzheimer’s trial data - Stock Titan
ProMIS Neurosciences Inc (PMN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ProMIS Neurosciences PMN310 shows early Alzheimer's promise - scanx.trade
ProMIS Neurosciences Inc (PMN) Income Statement - TradingKey
ProMIS Neurosciences to present interim Alzheimer’s trial data on PMN310 - TipRanks
ProMIS to host webinar on Alzheimer’s trial interim data - Investing.com
Promis Neurosciences Inc (PMN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Promis Neurosciences Inc 주식 (PMN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Kirwin Patrick D. | Director |
Apr 22 '26 |
Buy |
11.33 |
4,000 |
45,320 |
4,653 |
| Williams Eugene | Director |
Mar 05 '26 |
Buy |
24.40 |
2,000 |
48,800 |
12,397 |
| Williams Eugene | Director |
Mar 04 '26 |
Buy |
24.00 |
2,000 |
48,000 |
10,397 |
| Williams Eugene | Director |
Mar 02 '26 |
Buy |
22.53 |
1,000 |
22,530 |
7,397 |
| Williams Eugene | Director |
Mar 03 '26 |
Buy |
21.89 |
1,000 |
21,890 |
8,397 |
| Kaplan Johanne | Chief Development Officer |
Feb 19 '26 |
Buy |
15.35 |
1,629 |
25,005 |
3,941 |
| ABG Management Ltd. | 10% Owner |
Feb 03 '26 |
Buy |
12.13 |
700,741 |
8,499,988 |
943,090 |
| Milbury Max A. | Principal Accounting Officer |
Oct 03 '25 |
Buy |
0.49 |
30,392 |
14,929 |
45,389 |
1.80%
1.77%
자본화:
|
볼륨(24시간):